We are discussing the following Pooled Trial. O
Post# of 153880
(Total Views: 521)
Posted On: 05/28/2022 4:57:53 PM
Re: KenChowder #123895
We are discussing the following Pooled Trial.
Only 2 patients received monotherapy.
https://meetings.asco.org/abstracts-presentations/210205
Only 2 patients received monotherapy.
https://meetings.asco.org/abstracts-presentations/210205
Quote:
Methods:
mTNBC pts results from 3 blinded prospective clinical drug studies, Phase 1b/2 dose escalation (NCT03838367), Compassionate Use (NCT04313075), and Basket Study (NCT04504942) were pooled to evaluate leronlimab’s safety & efficacy at 12 months (mos). Pts received ≥1 dose of leronlimab alone (n = 2) , with carboplatin (n = 11) or with physician’s choice (n = 15) . Pts received 1-33 doses, ranging from 350mg (n = 9), 525mg (n = 16) or 700mg (n = 3). In addition, anonymized pt peripheral blood was procured before and after (̃30 days) induction as an exploratory biomarker, to evaluate TACs in predicting efficacy. Progressive disease, stable disease or partial response was determined by RESICT v1.1, and univariate analysis was used evaluate PFS & OS.
(0)
(0)